Article
Molecular genetic testing in the management of pituitary disease
29 Mar 2022
Abstract excerpt
OBJECTIVE: Most pituitary tumours occur sporadically without a genetically identifiable germline abnormality, a small but increasing proportion present with a genetic defect that predisposes to pituitary tumour development, either isolated (e.g., aryl hydrocarbon receptor-interacting protein, AIP) or as part of a tumour-predisposing syndrome (e.g., multiple endocrine neoplasia (MEN) type 1, Carney complex,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
